Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04118036
Title Abemaciclib + Pembrolizumab In Glioblastoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma

Therapies

Abemaciclib + Pembrolizumab

Age Groups: senior | adult | child
Covered Countries USA

Additional content available in CKB BOOST